
© 2025 ARIVA.de
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Di | BMS Heart Drug Camzyos Disappoints in Phase 3 Study | ||
Di | Why US Pharma Giant Bristol Myers Squibb Stock Trading Lower On Tuesday? | ||
Di | BMS' growth driver Camzyos fails in heart disease trial, denting expansion opportunity | ||
Di | Bristol Myers stumbles in bid to widen heart drug's use | ||
Di | BMO maintains Bristol-Myers $61 target after trial setback |